1. Anti-infection
  2. Bacterial

Kanamycin sulfate (Synonyms: Kanamycin A monosulfate)

Cat. No.: HY-16566A Purity: >98.0%
Data Sheet SDS Handling Instructions

Kanamycin (sulfate) is an aminoglycoside antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

For research use only. We do not sell to patients.
Kanamycin sulfate Chemical Structure

Kanamycin sulfate Chemical Structure

CAS No. : 25389-94-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in Water $55 In-stock
1 g $50 In-stock
5 g $80 In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


Kanamycin (sulfate) is an aminoglycoside antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.

In Vitro

Kanamycin sulfate at the concentration above 0.0025% has a significant inhibition on the growth of B. bifidum and has no influence on the other four probiotics at incubation 12 h or 24 h. The optimum selective concentration of kanamycin sulfate in MRS media is 0.005% for selective enumeration of B.bifidum[3].

In Vivo

The neurons damage of the DCN caused by kanamycin (500 mg/kg/day) is reversible and autophagy is upregulated in the neurotoxic course of kanamycin on DCN through JNK1-mediated phosphorylation of Bcl-2 pathway in rats. The serum BUN and Cr levels are both increased at the 1st day after the period of kanamycin administration. The neurons expressing LC3 are increased at 1, 7 and 14 days after kanamycin administration in comparison to the control group. Kanamycin treatment results in the increase of autophagy in a time-dependent manner[1]. Kanamycin sulfate (5 mg/kg) and sodium ampicillin (10 mg/kg) administered intramuscularly (i.m.) separately, and then together, to five pony mares, and the ampicillin concentration exceeds 5 mg/mL in inflamed synovial fluid for some 2.5 h after injection, and kanamycin sulfate concentration exceeds 2 mg/mL for 7 h in the pony[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02128308 Seoul National University Hospital Healthy November 2013 Phase 1
NCT00508690 Japan Multinational Trial Organization Colorectal Neoplasms September 2007 Phase 3
NCT00816426 National Institute of Allergy and Infectious Diseases (NIAID)|Korean Center for Disease Control and Prevention|International Tuberculosis Research Center|Novartis Institute for Tropical Medicine|Asian Medical Center|National Institutes of Health Clinical Center (CC) Tuberculosis December 29, 2008 Phase 1
NCT02409290 IUATLD, Inc|Medical Research Council MDR-TB April 2016 Phase 3
NCT02454205 University of Cape Town|University of Limpopo|Walter Sisulu University|University of Stellenbosch|University of Cape Town Lung Institute Tuberculosis|Multidrug Resistant Tuberculosis|Extensively-drug Resistant Tuberculosis October 2015 Phase 2|Phase 3
NCT00042289 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections March 2003 Phase 4
View MoreCollapse
Animal Administration

Kanamycin is formulated in vehicle (0.9% saline).

Sixty-six male Sprague-Dawley rats (initial body weight 125-150 g, 5-6 weeks old) have free access to water and a regular diet, and are allowed 1 week of acclimation before the first treatment. The animals are divided randomly into one control group and seven experimental groups. Control group rats (n=10) are injected subcutaneously with an equal volume of vehicle (0.9% saline) for 10 days as those in the groups of kanamycin treatment, but without kanamycin. The experimental groups (n=56, 8 for each group: 1, 7, 14, 28, 56, 70 and 140 days after kanamycin administration, respectively) receive 500 mg of kanamycin sulfate/kg/day by subcutaneous injection for 10 days. The animal body weight is monitored every day and the injection dosage of kanamycin is adjusted accordingly. Auditory thresholds are tested by ABR. The tests are taken twice for each animal, first prior to the beginning of administration and then at different observing time points after kanamycin treatment. Details for the ABR measurement is described elsewhere. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

H2O: ≥ 30 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Kanamycin sulfate
Cat. No.: